REDWOOD CITY, Calif.,
Oct. 22, 2013 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that it will release
third quarter 2013 financial results after market close on
Tuesday, November 5, 2013.
AcelRx management will host an investment-community
conference call at 4:30 p.m. eastern
time (1:30 p.m. pacific time)
on November 5, 2013 to discuss the
financial results and provide a corporate update.
Investors who wish to participate in the conference call may do
so by dialing (877) 870-4263 for domestic callers, (855) 669-9657
for Canadian callers or (412) 317-0790 for international callers.
Those interested in listening to the conference call live via the
internet may do so by visiting the Investors page of the company's
website at www.acelrx.com and clicking on the webcast link on the
Investors home page.
A webcast replay will be available on the AcelRx website for 90
days following the call by visiting the Investor page of the
company's website at www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso™, is designed
to solve the problems associated with post-operative intravenous
patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine,
the invasive IV route of delivery and the complexity of infusion
pumps. AcelRx has announced positive results from each of the
three Phase 3 clinical trials completed for Zalviso, and has
submitted an NDA to the FDA seeking approval for Zalviso to be used
to treat moderate-to-severe acute pain in the hospital
setting. AcelRx has also announced positive top-line results
for a Phase 2 trial for ARX-04, a product candidate for the
treatment of moderate-to-severe acute pain in a medically
supervised setting, funded through a grant from the U.S. Army
Medical Research and Materiel Command. The company has two
additional pain treatment product candidates, ARX-02 and ARX-03,
which have completed Phase 2 clinical development. For
additional information about AcelRx's clinical programs, please
visit www.acelrx.com.
Forward Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to the Phase 3
clinical trial data for Zalviso and the therapeutic potential of
Zalviso and AcelRx Pharmaceuticals' other product
candidates. These forward-looking statements are based on
AcelRx's current expectations and inherently involve significant
risks and uncertainties. AcelRx's actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to:
the fact that FDA may not accept for filing the Zalviso NDA;
AcelRx's ability to receive regulatory approval for Zalviso,
including whether the results of the Phase 3 clinical trials for
Zalviso are sufficient to obtain marketing approval for Zalviso,
which depends on the ability of AcelRx to demonstrate to the
satisfaction of the FDA the safety and efficacy of Zalviso based
upon its findings of the Phase 3 trials; any delays or inability to
obtain and maintain regulatory approval of its product candidates,
including Zalviso, in the United
States and Europe; its
ability to attract funding partners or collaborators with
development, regulatory and commercialization expertise; its
ability to obtain sufficient financing to commercialize Zalviso;
the market potential for its product candidates; and other
risks detailed in the "Risk Factors" and elsewhere in
AcelRx's U.S. Securities and Exchange Commission filings and
reports, including its Quarterly Report on Form 10-Q filed with the
SEC on August 12, 2013. AcelRx
undertakes no duty or obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or changes in its expectations.
(Logo:
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)
SOURCE AcelRx Pharmaceuticals, Inc.